Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Volkswagen Plant Could Pivot From Building Cars to Supporting Iron Dome Systems - 2Step by step instructions to Guarantee the Life span of Your Dental Inserts: Support and Care Guide
- 3First stop, the Moon. Next stop, Mars? Why Nasa's mission matters
- 4Pick Your Favored method of transportation
- 5Social Skylines d: A Survey of \Inside and out Social Experiences\ Language Learning Book
- Instructions to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- Nigeria police charge Joshua driver with dangerous driving over fatal crash
- 5 Great Youngster Care Administrations To Watch in 2024
- Step by step instructions to Get the Best Vehicle Rent Arrangement: Insider Tips and Systems
- The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results
- Toyota’s Next Big Sports Car Might Apparently Be a Turbocharged All-Paw Beast
- German journalists' union condemns attack on reporters in village
- The most effective method to Pick the Right Material Organization: Fundamental Tips
- Ferrari Cavalcade Suspended After High-Speed Crash in Argentina Involving a Purosangue
